Background: As part of the immune defense during infection, an increase in enzyme activity of indoleamine 2,3-dioxygenase (IDO) leads to a breakdown of tryptophan to kynurenine. In previous animal studies, therapeutic antagonism of IDO resulted in reduced sepsis mortality. We investigated the prognostic ability of tryptophan, serotonin, kynurenine and IDO (represented by the ratio of kynurenine/tryptophan) to predict adverse clinical outcomes in patients with community-acquired pneumonia (CAP). Methods: We measured tryptophan, serotonin and kynurenine on admission plasma samples from CAP patients included in a previous multicenter trial by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). We studied their association with inflammation (C-reactive protein), infection (procalcitonin) and clinical outcome. Results: Mortality in the 268 included patients was 45% within 6 years of follow-up. IDO and kynurenine showed a
Introduction
Tryptophan (TRP) is an essential amino acid and plays a key role in mammals as a precursor of physiological substances including serotonin 5-Hydroxytryptamine (5-HT) and melatonin [1] . Particularly TRP and its metabolites are thought to be altered during infections as part of the immune reaction [2, 3] . There are two metabolic pathways in the breakdown of TRP [4] (illustrated in Figure  1 ). About 95% of TRP is metabolized via the kynurenine (KYN) pathway. The rate-limiting enzymes are tryptophan 2,3-dioxygenase (TDO) localized in hepatic tissue and indoleamine 2,3-dioxygenase (IDO) in extrahepatic tissue. IDO is inducible by interferon-γ and is thus the rate limiting enzyme in an infective condition [5, 6] . The serotonin 5-HT pathway is catalyzed by tryptophan hydroxylase (TPH), whereas less than 5% of TRP is metabolized by this pathway [4] .
Initially, IDO was recognized as a potent antimicrobial effector molecule. Its antimicrobial effect was thought to exist through a breakdown of TRP as TRP is essential for the growth of microorganisms. However, recent studies have demonstrated its novel role as a strong inhibitor of T cell proliferation [2] . Sepsis-induced elevation of 5-HT has recently been discovered in a mouse model where high levels of 5-HT facilitated endothelial hyperpermeability [3] . Microvascular dysfunction is believed to contribute to patient mortality in sepsis [7] . Therefore an intervention with a 5-HT transporter inhibitor was speculated to be a potential therapeutic option [3] .
Community-acquired pneumonia (CAP) is currently the leading cause of death due to an infectious disease [8] and responsible for high costs, morbidity, and mortality worldwide [9, 10] . Serum activity of IDO predicted shortterm prognosis in a small cohort of 129 CAP patients [11] . However, this study did not measure serotonin. In a state of infection, the catabolism of TRP is activated [12] . Given these results from mostly animal studies, there is interest in a larger clinical study investigating how adaptations in the TRP/5-HT pathway interact with severity and outcome in patients with a well-defined infection. This will allow better understanding whether therapeutic interventions targeted at this pathway could bring benefits.
Herein, our aim was to investigate the association of metabolites of the TRP/5-HT pathway with severity and outcome in a well-characterized cohort of patients hospitalized for CAP with a follow-up over more than six years.
Materials and methods

Study design
A total of 268 patients hospitalized for CAP and available blood specimens from a previous Swiss multicenter trial [13, 14] were included in this analysis. The initial trial included 925 (68%) CAP patients in which all-cause mortality was 45% over a follow-up period of 6 years [15] .
The initial trial was a randomized controlled, antibiotic stewardship trial performed between October 2006 and March 2008 at six Swiss secondary and tertiary care centers and described elsewhere [13] . The primary goal of the study was to verify the efficacy and safety of using the procalcitonin (PCT) level to guide the initiation and duration of antibiotic therapy in patients with lower respiratory tract infections [13, 14] . Patients at least 18 years of age presenting from the community or a nursing home to the emergency department (ED) were included if they fulfilled at least one of the following criteria: cough, dyspnea, pleural pain, sputum production or tachypnea and one infectious sign (core body temperature > 38 °C, shivering, white blood cell count > 10 or < 4 cells × 10 9 L - 1 ) or one finding during auscultation (rales or crepitation). In all patients with CAP at that time an infiltrate was radiologically confirmed. Patients with language restriction or dementia that precluded from providing written informed consent, intravenous drug use, terminal condition or hospital-acquired pneumonia were excluded. Participants were allowed to receive corticosteroids or short-term antibiotic pretreatment but were excluded if they suffered from severe immunosuppression or received long-term antibiotic pretreatment at ED presentation.
The Ethics Committee of the University of Basel approved the initial study protocol and all patients provided written informed consent for the first trial including consent for the use of their data in secondary biomarker analyses and follow-up. The Pro-HOSP trial was registered at http://controlled-trials.com (identifier ISRCTN95122877).
Analysis of blood biomarker
Blood samples from all patients were collected upon ED admission. They were prepared to plasma and stored frozen at - 80 °C for later measurement of different blood markers.
The initial cohort consisted of 925 CAP patients. Baseline TRP, 5-HT, and KYN levels were measured in the plasma samples of 279 randomly selected subjects with available plasma samples. Therefore LC-MS/MS analysis was performed using an Ultimate 3000 UHPLC (Thermo Fisher, San Jose, USA) system coupled to an ABSciex 5500 quadrupole mass spectrometer (ABSciex, Darmstadt, Germany) and AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences AG, Innsbruck, Austria) as described in previous studies [16] [17] [18] . Briefly, a targeted profiling scheme is used to screen quantitatively for known small molecule metabolites using multiple reaction monitoring, neutral loss, and precursor ion scans. Quantification of the metabolites of the biological sample is achieved by reference to appropriate internal standards. Concentrations of all analyzed metabolites are reported in μmol/L [18] . Eleven measurements with a value of 0 μmol/L were excluded from our analysis because they were considered to be erroneous measurements. Based on the literature, normal range of TRP is at least 20 μmol/L or more [19] . Finally, we had a total number of 268 TRP, 250 KYN, and 213 5-HT measurements for statistical analysis.
In infection, a decrease of TRP and an increase of KYN at the same time was previously found [20, 21] . Thus, the ratio of KYN/ TRP was proposed to be a sensitive indicator of IDO activity and is widely used in current research [22] . The same principle was done for estimation of TPH.
Main outcome measurements
The primary endpoint was adverse outcome including 30-days allcause mortality or ICU admission. As secondary endpoints, mortality at 30 days and 6-year mortality were defined. Survival status has been confirmed by structured phone interviews through trained medical students at day 30, 180 and 540 and at 6 years [15, 23] . The pneumonia severity index (PSI) and quick sepsis-related organ failure assessment: altered mental status, fast respiratory rate ( ≥ 22 breaths per min), low blood pressure (systolic blood pressure ≤ 100 mmHg) (qSOFA) were used as first clinical assessment scores. PSI is composited by sex, past medical history, clinical, laboratory and radiological findings [24] . Altered mental status, fast respiratory rate ( ≥ 22 breaths per min) and low blood pressure (systolic blood pressure ≤ 100 mmHg) are used for qSOFA [25] .
Statistical analysis
All statistical analysis were performed using STATA 12.1 (Stata Corp, College Station, TX, USA) and p < 0.05 (two-tailed) was considered to indicate statistical significance. Unless stated otherwise, categorical variables are expressed as percentages (numbers) and continuous variables as medians [interquartile range (IQR)]. The distribution of the biomarkers TRP, 5-HT, and KYN were skewed. After logarithmic transformation with a base of 10, the distribution of the biomarker data approximated a normal distribution. First, we calculated Spearman rank correlation to investigate effects of the metabolites of the TRP/5-HT pathway and inflammation [assessed by C-reactive protein (CRP)], infection (assessed by PCT), sepsis severity (assessed by qSOFA) and CAP severity (assessed by PSI). Next, we used univariate and multivariate logistic regression models to examine the association of the metabolites and clinical outcomes, namely adverse outcome defined as death and/or ICU admission, as well as death, both within 30 days of follow-up. The multivariate models were adjusted for age, gender, and comorbidities. Also, univariate and multivariate Cox regression models were used to investigate associations between metabolites levels at baseline and all-cause mortality over 6 years. The area under curve (AUC) with 95% CI (confidence interval) is presented to illustrate discrimination and predictive power. KaplanMeier curves were used to represent mortality based on quartiles of the biomarkers (highest vs. lower three, except TRP lowest vs. higher three).
Results
Patient characteristics
Baseline characteristics of patients stratified by adverse outcome are presented in Table 1 . In general, patients with an adverse outcome were older and had a trend for a higher body mass index. There was a high burden of comorbidities with chronic kidney disease being more frequent in patients with an adverse outcome. Also, patients with an adverse clinical outcome had higher PSI and qSOFA-scores.
When looking at different metabolites of the TRP/5-HT pathway, we found a negative correlation of IDO 
Association of the tryptophan/serotonin pathway in inflammation and infection
In a first step, we investigated the association of the metabolites of the TRP/5-HT pathway with inflammation (assessed by CRP), infection (assessed by PCT), sepsis severity (assessed by qSOFA) and CAP severity (assessed by PSI). We found positive correlations of IDO with all of the markers above, particularly regarding PCT (Spearman rank: r 2 = 0.34, p < 0.001) and PSI (Spearman rank: r 2 = 0.39, p < 0.001) (see Table 2 ). Also, TRP was negatively correlated with CRP (Spearman rank: r 
Association of the tryptophan/serotonin pathway and adverse outcome
Next, we investigated the metabolites of the TRP/5-HT pathway with clinical outcomes. As illustrated in Figure 2 , TRP was lower (median 41.2 μmol/L vs. 52.2 μmol/L, p = 0.041) and the ratio of IDO was increased (median 101.2 vs. 67, p = 0.002) in patients with, as compared to those without an adverse outcome. This resulted in a trend of higher levels of KYN (median 4.3 μmol/L vs. 3.1 μmol/L, p = 0.088). There were no significant differences in 5-HT concentrations.
These results were also confirmed in Kaplan-Meier curves based on the highest quartile compared to the three lower quartiles to illustrate the association of the biomarkers with an adverse clinical outcome at 30 days ( Figure 3) . Because of the inverse association of TRP, we compared the lowest quartile with the three higher quartiles for TRP plasma levels. The strongest effect was seen for TRP (p log rank = 0.005) and IDO (p log rank = 0.011). No effect was found for 5-HT. 
Association between biomarkers and short-and long-term follow-up
Further, we also calculated univariate and multivariate regression analysis to investigate the association of metabolites of the TRP/5-HT pathway and short-term outcome (death and adverse outcome within 30 days) as well as long-term outcome (mortality within 6 years). As presented in Table 3 , TRP showed again an inverse association with an adverse short-term outcome [adjusted odds ratio (OR) 0.11 (95% CI 0.02-0.7), p = 0.021], but was not associated with long-term outcome. KYN was associated with short-and long-term outcome in univariate analysis. After multivariate adjustment, these associations were no longer significant. Similarly, IDO showed a significant association in univariate analysis, but in multivariate . Bold p-values are statistically significant at p < 0.05. CRP, C-reactive protein; PCT, procalcitonin; PSI, pneumonia severity index; qSOFA, quick sepsis-related organ failure assessment. analysis only short-term outcome remained significant. No associations were found for 5-HT.
Association of IDO with comorbidities
Finally, we conducted linear regression models to find out which comorbidities and parameters were associated with higher marker levels focusing on IDO, KYN, and TRP (Table 4 
Discussion
This study, examining the performance of metabolites of the TRP/5-HT pathway in a well-characterized cohort of CAP patients followed for over 6 years, revealed three key findings on hospital admission. First, we found a strong activation of IDO leading to a shift in metabolism from TRP to KYN dependent on infection, inflammation, and severity. No changes were found for circulating 5-HT levels. Second, higher levels of IDO and KYN, as well as lower levels of TRP were associated with clinical patient outcomes. These associations, however, were partly explained by age and comorbidities as effects in multivariate models were less impressive. Third, Multivariate model: adjusted for patient age, gender and comorbidities (coronary artery disease, congestive heart failure, chronic kidney disease, diabetes mellitus, neoplastic disease, pneumopathy, body mass index). the main parameters that influence the metabolites of the TRP/5-HT pathway were chronic kidney disease and age.
The present study showed a decrease of TRP in patients with CAP. This decrease correlated with higher disease severity as measured by higher levels of PCT and CRP, and higher risk scores (qSOFA and PSI). These results are in line with previous research [26] [27] [28] . The physiopathological mechanism of decreasing TRP during infection and inflammation is a matter of current discussion [29] . It has been hypothesized early on that diseaseassociated starvation and depletion by microbes may cause these effects. More recently, it has been proposed that the activation of the TRP/5-HT pathway is part of the host defense against infection and, thus, a beneficial adaptation [30] . These considerations are important because IDO can be therapeutically influenced, which in turn may impact the treatment and recovery of the infection. Recently, a particular substance that inhibits IDO has been developed and tested in animal models, namely the IDO inhibitor 1-methyl-tryptophan [31] . In a mouse model, IDO inhibitors potentiated cancer chemotherapy because of an immune-modulating effect of IDO [32] . Also, a blockade of IDO showed a reduction in mortality from peritonitis and sepsis in mice [27] . Despite these promising early results, clinical data is currently lacking demonstrating whether an IDO inhibitor could improve patient outcome in acute infection and sepsis. In this context, our clinical study showing a severity-dependent activation of IDO and a strong relationship to clinical outcome is relevant and may help to direct future interventional trials to answer the question, whether neutralization of the immunosuppressive effects could lead to a better infection control. Alternatively, an overwhelming reaction due to a suppression of the immune response in the human body would be possible. Only a few studies have investigated the impact of the TRP/5-HT metabolism in patients with CAP. Similarly to our study, Suzuki et al. [11] found an increase in IDO according to severity in a smaller cohort of CAP patients (129 subjects). Also, they studied short-term outcome and did multivariate regression analysis with laboratory parameters (e.g. CRP, blood urea nitrogen). The study, however, did not investigate long-term outcome, correlation with comorbidities and 5-HT was not assessed. Our results thus validate these findings, but also expand the results regarding metabolites and clinical significance.
We did not find an increase in 5-HT in patients according to severity and outcome. 5-HT is stored in platelets which are activated during infections resulting potentially in endothelial hyperpermeability [33] . This secretion depends on the 5-HT transporter (SERT) [34] . From our results, it remains unclear why there was no evidence for increased 5-HT levels according to the severity of an infection. Possibly, inhibition by SERT-inhibitors could lower the peripheral levels of 5-HT [3] . Alternatively, pre-analytical issues and low metabolite stability could explain the lack of association.
Further, we investigated factors associated with the activation of the TRP/5-HT pathway. In multivariate analysis, chronic kidney disease was found to be an important predictor for IDO and KYN elevation. This is also in line with previous studies reporting decreased TRP and increased KYN and IDO levels in chronic kidney disease [35] [36] [37] . Renal excretion is known to be the main route of KYN elimination [38] . As mentioned above, IDO levels were still associated with adverse events after adjustment for chronic kidney disease, indicating that elevated KYN levels are not attributable to renal excretory impairment alone, but also to up-regulated metabolism (e.g. systemic inflammation). It is evident, that chronic Inflammation is a significant burden to patients with chronic kidney disease and is elevated by disease progression [39] . As suggested by previous clinical trials, elevated IDO and KYN levels in chronic kidney diseases possibly indicate a chronic activation of the immune system [40] .
As a second factor, age was found to be associated with TRP and KYN. These findings are in line with current research and are possibly explained by chronic inflammation [41, 42] .
The main strengths of this study include (i) the wellcharacterized cohort of patients with CAP of different severities representative for patients usually treated in EDs and hospitals, (ii) the long and rigorous follow-up over a period of 6 years, and (iii) all-cause mortality as a primary outcome. Nevertheless, our study has limitations. First, this study was conducted in several hospitals in Switzerland, and results may not be generalizable to other countries. Second, autopsies were not performed to verify the causes of death and therefore this study focused on all-cause mortality rather than acute infection caused events. Third, this was an observational study and as such just hypothesis generating. Finally, the ratios of IDO and TPH are estimated and not measured. In future evaluations, complete measurements of all involved metabolites should be performed including plasma free TRP, determinants of TRP binding (albumin and nonesterified fatty acids), total TRP, TDO, IDO and levels of KYN metabolites [43] .
Conclusions
In hospitalized CAP patients, higher IDO activity and lower TRP levels independently predicted disease severity and short-term adverse outcome. Whether therapeutic modulation of IDO has positive effects on outcome needs further investigation.
